The FDA requested additional trial data, with researchers eager to continue psychedelic trials.
The FDA requested additional trial data, with researchers eager to continue psychedelic trials.
Connecticut, Missouri, and New Hampshire join 10 other states considering psychedelics bills.
States so far include Alaska, Arizona, California, Hawaii, Indiana, Illinois, Massachusetts, Maryland, New Jersey, and Wisconsin.
The FDA may receive a new drug application as early Q3 of 2023.
Across the nation, not only is marijuana growing more accepted, but so are other drugs like psilocybin and MDMA.
Phase 3 studies are underway, and current research sees potential for MDMA in psychotherapy.
Our Chief Medical Officer and VP of Clinical Services comment on the clinical use of ecstasy and marijuana.
